<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25120088</article-id>
      <article-id pub-id-type="pmc">4126766</article-id>
      <article-id pub-id-type="doi">10.5935/abc.20140098</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Bioresorbable Vascular Scaffold Use in a Case of In-stent
Restenosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Cadrin-Tourigny</surname>
            <given-names>Julia</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dong</surname>
            <given-names>Liang</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maehara</surname>
            <given-names>Akiko</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schampaert</surname>
            <given-names>Erick</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Genereux</surname>
            <given-names>Philippe</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="aff" rid="aff02">2</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> H&#xF4;pital du Sacr&#xE9;-Coeur de Montr&#xE9;al, Qu&#xE9;bec, Canada</aff>
      <aff id="aff02"><label>2</label> Columbia University Medical Center and the Cardiovascular Research
Foundation, New York, New York - USA</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing Address: Philippe Genereux,</bold> 111 E, 59th street 12th floor.
Postal Code 10023, New York, NY - USA. E-mail: <email>pgenereux@crf.org</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <volume>103</volume>
      <issue>1</issue>
      <fpage>e11</fpage>
      <lpage>e14</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>10</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>12</day>
          <month>11</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>11</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>Stents</kwd>
        <kwd>Coronary Artery Disease</kwd>
        <kwd>Cardiac Catheterization</kwd>
        <kwd>Bioresorbable Vascular Scaffold</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>Abbreviation list</bold>
    </p>
    <p><bold>BMS -</bold> Bare metal stent</p>
    <p><bold>BVS -</bold> Bioresorbable vascular scaffold</p>
    <p><bold>DES -</bold> Drug-eluting stent</p>
    <p><bold>ISR -</bold> In-stent restenosis</p>
    <p><bold>LAD -</bold> Left anterior descending</p>
    <p><bold>OCT -</bold> Optical coherence tomography</p>
    <p><bold>PCI -</bold> Percutaneous coronary intervention</p>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Bioresorbable vascular scaffolds (BVS) demonstrate favourable outcomes in patients with
stable coronary disease with simple de novo coronary lesions<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup> and are
considered the "fourth revolution" in percutaneous coronary intervention (PCI)
technology. BVS represent a promising alternative to drug-eluting stents (DES) while
offering the same advantages. We present the first case of in-stent restenosis (ISR)
successfully treated with an everolimus-eluting BVS (ABSORB; Abbott Vascular, Santa
Clara, CA) and discuss its potential advantages in such lesion.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>A 72-year-old male presented with a 3-week history of relapsing Canadian Cardiovascular
Society class 3/4 angina. He had undergone PCI of the proximal left anterior descending
(LAD) 4 years prior using a 2.75 x 18 mm sirolimus-eluting stent (Cypher Cordis, Miami,
FL). His medical regimen included aspirin and a statin. Resting ECG and cardiac
biomarkers were normal. Given the severity of his symptoms and his past medical history,
it was decided to proceed directly to coronary angiography.</p>
      <p>The coronary angiogram showed a severe 95% ISR lesion of the proximal LAD with thrombus
and multiple areas of contrast staining outside the stent contour, compatible with
coronary micro-aneurysms (<xref ref-type="fig" rid="f01">Figure 1A</xref>).
Thromboaspiration revealed white thrombus. Optical coherence tomography (OCT) was
compatible with a localized hypersensitivity reaction to first-generation DES (<xref ref-type="fig" rid="f01">Figure 1B</xref>). After consensus with the referring
physician, an ABSORB everolimus-eluting BVS 3.0 x 18 mm was deployed (<xref ref-type="fig" rid="f02">Figure 2A</xref>). Repeated OCT showed good scaffold
apposition and coverage of the micro-aneurysms (<xref ref-type="fig" rid="f02">Figure
2B</xref>). The patient was discharged the following day on dual antiplatelet therapy
with aspirin and ticagrelor. The patient was asymptomatic at 6 months clinical
follow-up.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Baseline Angiogram and Optical Coherence Tomography</p>
          <p>(A) Baseline angiogram showing a severe restenotic lesion of the proximal left
anterior descending artery with 2 micro-aneurysms (asterisk), with contrast
staining outside the previously implanted drug-eluting stent suggesting
late-acquired malapposition secondary to hypersensitivity vasculitis. (B) Optical
coherence tomography performed after initial thrombectomy and balloon dilatation
angioplasty showing typical late acquired malapposition features with &#x201C;sunflower&#x201D;
appearance (top right panel) and 2 small pockets representing micro-aneurysms
(asterisk; lower panel).</p>
        </caption>
        <graphic xlink:href="abc-103-01-0e11-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Post PCI Angiogram and Optical Coherence Tomography</p>
          <p>(A) Final coronary angiography showing exclusion of the 2 micro-aneurysms present
at baseline. (B) Final optical coherence tomography showing good BVS apposition
with covering of the 2 micro-aneurysms and thrombus entrapment.</p>
        </caption>
        <graphic xlink:href="abc-103-01-0e11-g02"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>To the best of our knowledge, this is the first report describing the use of a BVS in a
case of ISR and late acquired malapposition secondary to first-generation DES. The
ABSORB BVS consists of resorbable polymers containing the antiproliferative drug
everolimus. Prospective studies of BVS showed favourable outcomes in simple, de novo
coronary lesions<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup>, with long-term positive vessel remodelling, late lumen
enlargement, complete resorption of the vascular scaffold, and progressive filling of
the previously occupied space with proteoglycans at follow-up<sup><xref rid="r03" ref-type="bibr">3</xref></sup>. However, these studies specifically excluded ISR
lesions.</p>
      <p>In the current report, a local delayed hypersensitivity vasculitis caused by a
sirolimus-eluting stent was suspected to be the causal mechanism leading to late
acquired stent malapposition, restenosis, with superimposed very late
thrombosis<sup><xref rid="r04" ref-type="bibr">4</xref></sup>. Typical
angiographic findings present in our patient, including positive remodelling and
micro-aneurysms of the mid-segment of the stent. This hypersensitivity reaction has been
attributed to the polymer coating of sirolimus-eluting stents, which, importantly,
differs from the one used in the ABSORB BVS<sup><xref rid="r04" ref-type="bibr">4</xref></sup>.</p>
      <p>In this particular case, the use of BVS had several advantages: avoidance of
accumulation of multiple layers of metallic stent, avoidance of re-exposure to the same
"allergic antigen" and most importantly, hypothetically, the healing process of BVS
characterized by late lumen enlargement and replacement of the platform by
proteoglycans, resulting in filling of the micro-aneurysms and exclusion of the nidus
involved in the genesis of neo-thrombi. Angiographic follow-up with OCT imaging at 2
years or beyond will potentially validate the latest hypothesis.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>BVS are a promising addition to the PCI arsenal in managing complex coronary lesions.
This case report demonstrates novel use of this technology to treat an ISR lesion of DES
characterized by late acquired malapposition.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>
          <bold>Potential Conflict of Interest</bold>
        </p>
        <p>The author Erick Schampaert has conflict with Abbott Vascular Consultant and Philippe
Genereux has conflict with Abbott Vascular Speaker Fee.</p>
      </fn>
      <fn fn-type="con">
        <p>
          <bold>Author contributions</bold>
        </p>
        <p>Cadrin-Tourigny J and Dong L, conception and design of the research, acquision of
data, analysis and interpretation of the data, statistical analysis, writing of the
manuscript and critical revision of the manuscript for intellectual content; Maehara
A, conception and design of the research, acquision of data, analysis and
interpretation of the data, obtaining financing, writing of the manuscript, critical
revision of the manuscript for intellectual content; Schampaert E and Genereux P,
conception and design of the research, acquision of data, analysis and interpretation
of the data, writing of the manuscript, critical revision of the manuscript for
intellectual content.</p>
      </fn>
      <fn fn-type="other">
        <p>
          <bold>Sources of Funding</bold>
        </p>
        <p>There were no external funding sources for this study.</p>
      </fn>
      <fn fn-type="other">
        <p>
          <bold>Study Association</bold>
        </p>
        <p>This study is not associated with any thesis or dissertation work.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ormiston</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Serruys</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Regar</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dudek</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Thuesen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Webster</surname>
              <given-names>MW</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>A bioabsorbable everolimus-eluting coronary stent system for patients
with single de-novo coronary artery lesions (ABSORB): a prospective open-label
trial</article-title>
          <source>Lancet</source>
          <year>2008</year>
          <volume>371</volume>
          <issue>9616</issue>
          <fpage>899</fpage>
          <lpage>907</lpage>
          <pub-id pub-id-type="pmid">18342684</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Serruys</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Onuma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ormiston</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>de Bruyne</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Regar</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dudek</surname>
              <given-names>D</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Evaluation of the second generation of a bioresorbable everolimus
drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis:
six-month clinical and imaging outcomes</article-title>
          <source>Circulation</source>
          <year>2010</year>
          <volume>122</volume>
          <issue>22</issue>
          <fpage>2301</fpage>
          <lpage>2312</lpage>
          <pub-id pub-id-type="pmid">21098436</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Serruys</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Ormiston</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Onuma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Regar</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gonzalo</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Garcia-Garcia</surname>
              <given-names>HM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>A bioabsorbable everolimus-eluting coronary stent system (ABSORB):
2-year outcomes and results from multiple imaging methods</article-title>
          <source>Lancet</source>
          <year>2009</year>
          <volume>373</volume>
          <issue>9667</issue>
          <fpage>897</fpage>
          <lpage>910</lpage>
          <pub-id pub-id-type="pmid">19286089</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Virmani</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Guagliumi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Farb</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Musumeci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Grieco</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Motta</surname>
              <given-names>T</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Localized hypersensitivity and late coronary thrombosis secondary to a
sirolimus-eluting stent: should we be cautious?</article-title>
          <source>Circulation</source>
          <year>2004</year>
          <volume>109</volume>
          <issue>6</issue>
          <fpage>701</fpage>
          <lpage>705</lpage>
          <pub-id pub-id-type="pmid">14744976</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
